Results 91 to 100 of about 1,701 (184)

Abstract Supplement HIV Glasgow 8–11 November 2026, Glasgow, UK/Virtual

Journal of the International AIDS Society, Volume 29, Issue S6, November 2026.
wiley   +1 more source

Beyond Efficacy: The Access, Delivery Systems, Acceptability, Persistence, and Transition Management “ADAPT” Framework for Long-Acting Injectable PrEP in Sub-Saharan Africa

HIV/AIDS: Research and Palliative Care
Eric Nzirakaindi Ikoona,1 Lucy Namulemo,2 Ronald Kaluya,3 Rebecca Ikoona,4 Foday Sahr51Department of Evaluation and Research, National Public Health Agency, Freetown, Sierra Leone; 2Department of Treatment Services, Foothills Community-Based ...
Ikoona EN, Namulemo L, Kaluya R, Ikoona R, Sahr F   +4 more
doaj  

Multi-Center Real-World Implementation Outcomes of Lenacapavir for HIV Pre-Exposure Prophylaxis

Lenacapavir PrEP implementation across 17 U.S. sites (n=501) was characterized by delays in initiation driven by payer processes. Early non-persistence was uncommon (3.6%) but exceeded clinical trial discontinuation rates and was strongly associated with
Cannon, Chase A, Narcisse-Cempini, Gilianne, Multani, Ami, Gipson, June, Turner, Christian, Kunzmann, Leah, Chan, Philip A, Clement, Meredith, Spinelli, Matthew, Havens, Joshua P, Springer, Sandra A, Cherabie, Joesph, Lillis, Rebecca, Taraschi, Ellen, Butler, Isolde, Vail, Rona, Sukumaran, Stephen, Patel, Rupa R, Hazra, Aniruddha, Blumenthal, Jill, Kaperak, Christopher J, Doblecki-Lewis, Susanne, Smith, Romini, Halbur, Drew, Safa, Hussein   +24 more
core   +1 more source

An Engineered Aminotransferase for the Synthesis of a Key Chiral Intermediate of Lenacapavir [PDF]

We report the development of an engineered aminotransferase for the synthesis of a key chiral intermediate of the anti-HIV drug Lenacapavir. Due to the sterically demanding nature of the ketone substrate, a substrate walking approach was adopted during ...
Nicholas, Turner, Amy, Hutton, Fei, Zhao, Ian, Rowles, William, Finnigan, Grayson, Ford, Georgia, Harris, Anthony, Green   +7 more
core   +1 more source

Preparation of a Key Intermediate En Route to the Anti-HIV Drug Lenacapavir

A very efficient four-step synthesis of the main fragment of Gilead’s anti-HIV drug lenacapavir is described. The route showcases a 1,2-addition to an intermediate aldehyde using an organozinc halide derived from a commercially available difluorobenzyl ...
Yuting Hu (322619), Bruce H. Lipshutz (1330881), Juan C. Caravez (12495731), Erfan Oftadeh (17797153), Kirubel T. Mamo (18115323)   +4 more
core   +1 more source

Efficacy and Safety of Bictegravir Plus Lenacapavir: 48-Week Outcomes in People With HIV-1 Who Are Virologically Suppressed on Complex Antiretroviral Regimens at Baseline

ARTISTRY-1 is a phase 2/3 trial of bictegravir (BIC; 75 mg) plus lenacapavir (LEN; 25 mg or 50 mg) versus complex antiretroviral therapy regimens in 128 virologically suppressed people with HIV-1.
Sklar, Peter, Santana, Jorge, Aizen, Keith, Mounzer, Karam, Hedgcock, Malcolm, Montezuma-Rusca, Jairo M., Zhang, Xu, Bloch, Mark, Segal-Maurer, Sorana, Slim, Jihad, Ramgopal, Moti   +10 more
core   +1 more source

Noticiero farmacológico

Revista del Hospital de Niños
Sección a Cargo de Patricia Cardoso y Raúl Plager Caspofungina: evitar membranas derivadas de poliacrilonitrilo durante el tratamiento sustitutivo renal continuo. Dinutuximab beta: síndrome urémico hemolítico atípico.
Patricia Cardoso, Raúl Plager
doaj   +2 more sources

Acceptability and Implementation Considerations for Twice-Yearly Injectable Lenacapavir PrEP in Kazakhstan: An Exploratory Mixed-Methods Study

This exploratory mixed-methods study examines acceptability of twice-yearly injectable lenacapavir for HIV pre-exposure prophylaxis (PrEP) among key populations (gay, bisexual, and other men who have sex with men; people who use drugs; sex workers ...
Indira Karibayeva, Gulmira Abdiraiymova, Sholpan Primbetova, Assel Terlikbayeva, Janina Steinert, Elena German, Sairankul Kassymbekova, Susanna Rinne-Wolf, Akhan Nurtazin, Nikolay Lunchenkov, Aruzhan Saimasova   +10 more
core   +1 more source

Correction to: Lenacapavir: First Approval

Drugs, 2023
openaire   +1 more source

LenacDr. Pasham Umaapavir and Long-Acting HIV Therapeutics Pharmacological Mechanisms, Clinical Evidence from the PURPOSE Trials, and Future Directions in Antiretroviral Therapy

Lenacapavir (Sunlenca for treatment; Yeztugo for prevention) is a first-in-class HIV-1 capsid inhibitor with an unprecedented pharmacokinetic profile enabling subcutaneous administration only twice yearly, representing a transformative advance in both ...
Dr. Pasham Uma, Ch. Sreya Sri, Muvvala Sudhakar, Dr. R. L. Manisha   +3 more
core   +1 more source